Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Jefferies Downgrades Medifast to Hold, Lowers Price Target to $150

Jefferies analyst Stephanie Wissink downgrades Medifast (NYSE:MED) from Buy to Hold and lowers the price target from $345 to $150.
byBenzinga Newsdesk
August 4, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Jefferies analyst Stephanie Wissink downgrades Medifast (NYSE:MED) from Buy to Hold and lowers the price target from $345 to $150.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Brixmor Property Group Inc. Announces Angela M. Aman, Has Been Promoted To The Additional Position Of President, And Brian T. Finnegan, Has Been Promoted To Senior Executive Vice President And Chief Operating Officer

By Benzinga Newsdesk
September 28, 8:03 AM
Brixmor Property Group Inc. (NYSE:BRX) ("Brixmor" or the "Company") announced today that Angela M. Aman, currently the Company's Executive Vice President, Chief Financial Officer and Treasurer, has been promoted to the

BRX